-
Plerixafor, sold
under the
brand name Mozobil, is an
immunostimulant used to
mobilize hematopoietic stem
cells in
cancer patients into the bloodstream...
-
antagonist plerixafor". Blood. 123 (15): 2308–2316. doi:10.1182/blood-2013-09-527226. ISSN 0006-4971. PMC 3983611. PMID 24523241. "
Plerixafor Versus G-CSF...
-
through different mechanisms. CXCL2 in
combination with the CXCR4
inhibitor plerixafor rapidly mobilizes hematopoietic stem
cells into the
peripheral blood....
- that MSCs for
prophylactic reason reduce the
incidence of
chronic GvHD.
Plerixafor (Mozobil) was
approved for
medical use in the
United States in 2008. Motixafortide...
- (INN)
Plavix pleconaril (INN)
Plegine Plegisol Plenaxis Plendil Plenvu plerixafor (USAN, (INN))
Pletal pleuromulin (INN)
plicamycin (INN)
plinabulin (USAN...
- pancreatitis. For instance,
blocking CXCR4, the
receptor for CXCL12, with
Plerixafor (AMD-3100)
increased the
effectiveness of
combretastatin in a
mouse model...
- iron
deficiency anemia.
Fludara (Fludarabine), for leukemia.
Mozobil (
Plerixafor), for macrocycle,
approved by the FDA for
peripheral blood stem cell mobilizer...
-
ether with
alternating (CH2)2 and (CH2)3
linkers between amine centers.
Plerixafor, a
derivative of cyclam, is used to
treat lymphoma and
multiple myeloma...
- cancer.
Macrocyclic ligands have been
utilised as CXCR4 antagonists.
Plerixafor is an
example of a CXCR4 antagonist, and has
approvals (e.g. US FDA 2008)...
-
elastase in the bone
marrow leading to
proteolytic degradation of SDF-1.
Plerixafor (AMD3100) is a drug,
approved for
routine clinical use,
which directly...
